Cancer News and Research

Latest Cancer News and Research

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

States push for insurers to increase coverage

States tackle several health care policy issues focused on health insurance coverage mandates and requirements.

12 Feb 2010

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

OPKO Health, Inc. today announced the development of a simple diagnostic blood test for Alzheimer’s disease. The test, designed to detect elevated levels of antibodies unique to Alzheimer’s disease, was approximately 95% accurate in initial testing.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Researchers discover cancer gene in ancestral metazoan

To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.

12 Feb 2010

New amplitude gating technique helps scanners pinpoint tumors

When one diagnoses a cancer patient, it's important to gather as much information about that person as possible. But who would have thought an accurate diagnosis would depend on throwing some of that information away?

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

Biological-based therapies are alternative medicines for women recovering from breast cancer

Biological-based therapies such as diet supplements and vitamins are the most popular complementary and alternative medicines for women recovering from breast cancer, according to a Michigan State University researcher working to create a support intervention for women in treatment for the disease.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Emory-UGA IPIRC to host symposium on H1N1 virus

The Emory - University of Georgia Influenza Pathogenesis and Immunology Research Center will host a symposium April 18 - 20 at the Emory Conference Center featuring an international roster of speakers.

11 Feb 2010

Decline in breast cancer rates linked to race, ethnicity and economic background

Breast cancer rates are declining, but some groups have seen a more significant decline than others, with race, ethnicity and economic background playing a part.

11 Feb 2010

Mayo Clinic provides treatment options for aging skin

Age or liver spots -- These flat, brown areas, also called solar lentigos, typically occur on the hands, back and face. Using a topical retinoid -- often in conjunction with bleaching cream and a mild topical steroid -- may gradually fade an age spot.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

Cancer News and Research

Latest Cancer News and Research

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

States push for insurers to increase coverage

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Researchers discover cancer gene in ancestral metazoan

New amplitude gating technique helps scanners pinpoint tumors

New screening system developed to discover molecules that block HCV life cycle

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

Biological-based therapies are alternative medicines for women recovering from breast cancer

British rhubarb could be a potential source of anti-cancer agent

Emory-UGA IPIRC to host symposium on H1N1 virus

Decline in breast cancer rates linked to race, ethnicity and economic background

Mayo Clinic provides treatment options for aging skin

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

hESC and iPSC: Long-term stem cell evaluation and comparison study

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in